SunTrust analyst Joon Lee kept his Buy rating and $20 price target on La Jolla, saying the stock price remains undervalued despite the 92% rally yesterday on the news that its phase 2 LJPC-401 study in hereditary hemochromatosis, or HH, resulted in "statistic significance". The analyst notes that some 640K - 1.6M HH patients exist in in the U.S., and given '401's superior efficacy and tolerability, its pricing may come at a premium relative to the $15K/year option for Exjade. Lee adds that the market assessment of HH prevalence is clouded by the tendency for the disease to be "under-diagnosed".